These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 11454918)

  • 1. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
    Millan MJ; Gobert A; Lejeune F; Newman-Tancredi A; Rivet JM; Auclair A; Peglion JL
    J Pharmacol Exp Ther; 2001 Aug; 298(2):565-80. PubMed ID: 11454918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
    Millan MJ; Dekeyne A; Papp M; La Rochelle CD; MacSweeny C; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2001 Aug; 298(2):581-91. PubMed ID: 11454919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.
    Bymaster FP; Dreshfield-Ahmad LJ; Threlkeld PG; Shaw JL; Thompson L; Nelson DL; Hemrick-Luecke SK; Wong DT
    Neuropsychopharmacology; 2001 Dec; 25(6):871-80. PubMed ID: 11750180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.
    Millan MJ; Gobert A; Rivet JM; Adhumeau-Auclair A; Cussac D; Newman-Tancredi A; Dekeyne A; Nicolas JP; Lejeune F
    Eur J Neurosci; 2000 Mar; 12(3):1079-95. PubMed ID: 10762339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.
    Koch S; Hemrick-Luecke SK; Thompson LK; Evans DC; Threlkeld PG; Nelson DL; Perry KW; Bymaster FP
    Neuropharmacology; 2003 Dec; 45(7):935-44. PubMed ID: 14573386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat.
    Béïque J; de Montigny C; Blier P; Debonnel G
    Neuropharmacology; 2000 Jul; 39(10):1813-22. PubMed ID: 10884562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
    Orjales A; Mosquera R; Toledo A; Pumar MC; García N; Cortizo L; Labeaga L; Innerárity A
    J Med Chem; 2003 Dec; 46(25):5512-32. PubMed ID: 14640559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with alpha/beta-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors.
    Millan MJ; Dekeyne A
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):579-93. PubMed ID: 17076935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies.
    Bel N; Artigas F
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1064-72. PubMed ID: 8819487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.
    Béïque JC; Lavoie N; de Montigny C; Debonnel G
    Eur J Pharmacol; 1998 May; 349(1):129-32. PubMed ID: 9669506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat.
    Béïque J; de Montigny C; Blier P; Debonnel G
    Neuropharmacology; 2000 Jul; 39(10):1800-12. PubMed ID: 10884561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems.
    Rueter LE; De Montigny C; Blier P
    J Pharmacol Exp Ther; 1998 May; 285(2):404-12. PubMed ID: 9580577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors.
    Miller DK; Wong EH; Chesnut MD; Dwoskin LP
    J Pharmacol Exp Ther; 2002 Aug; 302(2):687-95. PubMed ID: 12130733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors.
    Gobert A; Millan MJ
    Neuropsychopharmacology; 1999 Aug; 21(2):268-84. PubMed ID: 10432475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems.
    Gould GG; Pardon MC; Morilak DA; Frazer A
    Neuropsychopharmacology; 2003 Sep; 28(9):1633-41. PubMed ID: 12825093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study.
    Hébert C; Habimana A; Elie R; Reader TA
    Neurochem Int; 2001 Jan; 38(1):63-74. PubMed ID: 10913689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
    Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O
    Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
    Vaishnavi SN; Nemeroff CB; Plott SJ; Rao SG; Kranzler J; Owens MJ
    Biol Psychiatry; 2004 Feb; 55(3):320-2. PubMed ID: 14744476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites.
    Béïque JC; de Montigny C; Blier P; Debonnel G
    Synapse; 1999 Jun; 32(3):198-211. PubMed ID: 10340630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.